YU2703A - Bistar vodeni anestetski preparat - Google Patents

Bistar vodeni anestetski preparat

Info

Publication number
YU2703A
YU2703A YU2703A YUP2703A YU2703A YU 2703 A YU2703 A YU 2703A YU 2703 A YU2703 A YU 2703A YU P2703 A YUP2703 A YU P2703A YU 2703 A YU2703 A YU 2703A
Authority
YU
Yugoslavia
Prior art keywords
clear aqueous
propofol
compositions
anesthetic composition
composition
Prior art date
Application number
YU2703A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Srikanth Annappa Pai
Sangeeta Hanurmesh Rivankar
Shilpa Sudhakar Kocharekar
Original Assignee
Bharat Serums & Vaccines Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd. filed Critical Bharat Serums & Vaccines Ltd.
Publication of YU2703A publication Critical patent/YU2703A/sh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
YU2703A 2000-06-21 2000-12-14 Bistar vodeni anestetski preparat YU2703A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN573MU2000 IN187686B (enExample) 2000-06-21 2000-06-21

Publications (1)

Publication Number Publication Date
YU2703A true YU2703A (sh) 2006-03-03

Family

ID=11097257

Family Applications (1)

Application Number Title Priority Date Filing Date
YU2703A YU2703A (sh) 2000-06-21 2000-12-14 Bistar vodeni anestetski preparat

Country Status (26)

Country Link
US (1) US7138387B2 (enExample)
EP (1) EP1299095B1 (enExample)
JP (1) JP4907833B2 (enExample)
KR (1) KR100810066B1 (enExample)
CN (1) CN1254237C (enExample)
AP (1) AP2002002674A0 (enExample)
AT (1) ATE267592T1 (enExample)
AU (2) AU2001235972B2 (enExample)
BG (1) BG107463A (enExample)
BR (1) BR0017268A (enExample)
CA (1) CA2414064C (enExample)
DE (1) DE60011149T2 (enExample)
DK (1) DK1299095T3 (enExample)
EA (1) EA005589B1 (enExample)
ES (1) ES2222271T3 (enExample)
HU (1) HUP0301646A3 (enExample)
IL (1) IL153387A0 (enExample)
IN (1) IN187686B (enExample)
MX (1) MXPA02012611A (enExample)
NO (1) NO20025999D0 (enExample)
NZ (1) NZ523643A (enExample)
PL (1) PL359624A1 (enExample)
PT (1) PT1299095E (enExample)
WO (1) WO2001097796A1 (enExample)
YU (1) YU2703A (enExample)
ZA (1) ZA200300336B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188917B (enExample) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
NZ533536A (en) * 2001-12-28 2006-11-30 Mgi Gp Inc Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol such as O-phosphonooxymethyl propofol
EP1469886B8 (en) * 2002-02-01 2008-01-09 Shimoda Biotech (PTY) LTD Lyophilized pharmaceutical composition of propofol
NZ538255A (en) * 2002-07-29 2006-11-30 Transform Pharmaceuticals Inc Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
EP1585548B1 (en) * 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
EP1704858A4 (en) * 2004-01-14 2008-06-04 Otsuka Pharma Co Ltd PROPOFOL-CONTAINING FAT-EMULSION PREPARATION
WO2006030450A2 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
EP1928412B1 (en) * 2005-08-12 2015-09-16 Bharat Serums & Vaccines Ltd. Aqueous anaesthetic compositions comprising propofol
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
TWI450043B (zh) * 2008-03-11 2014-08-21 3M Innovative Properties Co 具備保護層之光工具
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
EP2456823A4 (en) 2009-07-21 2012-12-26 3M Innovative Properties Co CURABLE COMPOSITION, METHOD FOR COATING A PHOTO TOOL, AND COATED PHOTO TOOL
EP2478034A1 (en) 2009-09-16 2012-07-25 3M Innovative Properties Company Fluorinated coating and phototools made therewith
KR101781659B1 (ko) 2009-09-16 2017-09-25 쓰리엠 이노베이티브 프로퍼티즈 컴파니 플루오르화된 코팅 및 그로 제조된 포토툴
US8268067B2 (en) * 2009-10-06 2012-09-18 3M Innovative Properties Company Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (de) * 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
DK2484350T3 (en) * 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
WO2013078500A1 (en) 2011-11-29 2013-06-06 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
CN103263404B (zh) * 2012-04-28 2017-12-01 中国人民解放军军事医学科学院放射与辐射医学研究所 一种复合麻醉药物
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
US10646439B2 (en) * 2016-01-29 2020-05-12 Cuda Anesthetics, Llc Aqueous pharmaceutical formulation comprising propofol
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition

Also Published As

Publication number Publication date
PL359624A1 (en) 2004-08-23
HUP0301646A3 (en) 2005-06-28
NO20025999L (no) 2002-12-13
ES2222271T3 (es) 2005-02-01
KR100810066B1 (ko) 2008-03-05
IN187686B (enExample) 2002-06-08
JP4907833B2 (ja) 2012-04-04
DK1299095T3 (da) 2004-10-11
MXPA02012611A (es) 2004-07-30
EA200300047A1 (ru) 2003-06-26
IL153387A0 (en) 2003-07-06
BR0017268A (pt) 2003-05-27
CA2414064A1 (en) 2001-12-27
ATE267592T1 (de) 2004-06-15
US20040014718A1 (en) 2004-01-22
EP1299095A1 (en) 2003-04-09
EA005589B1 (ru) 2005-04-28
DE60011149D1 (de) 2004-07-01
AU2001235972B2 (en) 2005-07-21
CA2414064C (en) 2013-01-08
DE60011149T2 (de) 2005-07-07
WO2001097796A1 (en) 2001-12-27
US7138387B2 (en) 2006-11-21
JP2003535893A (ja) 2003-12-02
ZA200300336B (en) 2004-04-08
AU3597201A (en) 2002-01-02
CN1254237C (zh) 2006-05-03
NZ523643A (en) 2004-05-28
CN1454085A (zh) 2003-11-05
EP1299095B1 (en) 2004-05-26
BG107463A (en) 2003-11-28
PT1299095E (pt) 2004-10-29
HUP0301646A2 (hu) 2003-09-29
NO20025999D0 (no) 2002-12-13
AP2002002674A0 (en) 2002-12-31
KR20030023875A (ko) 2003-03-20

Similar Documents

Publication Publication Date Title
YU2703A (sh) Bistar vodeni anestetski preparat
UA91512C2 (ru) Коньюгати олигомеров инсулина, их композиция (варианты) и применение
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
SE0001899D0 (sv) New compounds
AR046651A1 (es) Composicion purgante colonica con agente aglutinante soluble
DE60133555D1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
PT1390039E (pt) Utilizacao de compostos estrogenicos para aumentar a libido nas mulheres
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
CO6251259A2 (es) Formulaciones farmaceuticas de estriol en baja dosis
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004779A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
AR065816A1 (es) Regimen anticonceptivo oral
BRPI0409380A (pt) composições farmacêuticas
AR043110A1 (es) Sal de heparina de bajo peso molecular con trietanolamina util como agente terapeutico-antitrombotico de administracion topica, procedimientos para preparar dichas sales, proceso para la eliminacion de la higroscopicidad de la sal de heparina, composiciones farmaceuticas para uso topico en terapia a
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
AR007854A1 (es) Compuestos de bromotiacumicina, composiciones farmaceuticas que los contienen, el uso de dichos compuestos para la manufactura de un medicamento y un procedimiento para su preparacion
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
NZ523606A (en) Pharmaceutical compositions and methods for use
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi